Vernonanthura polyanthes (Spreng.) A.J. Vega & Dematt. (syn.: Vernonia polyanthes Less) is popularly known as “assa-peixe” and its leaves are used in folk medicine mainly to treat respiratory diseases. In this study, we evaluated the cytogenotoxic and anticytogenotoxic potential of the V. polyanthes leaf aqueous extract (VpLAE) and its n-butanol fraction (n-BF) in the presence or absence of doxorubicin (DXR) (pre-, co-, and post-treatments) on a murine model for 24 h or 120 h. The micronucleus test (MN) and the comet assay were used to assess the cytogenotoxic and anticytogenotoxic potential of VpLAE and n-BF (250, 500, and 1000 mg/kg) administered via gavage to Swiss Webster mice. The chemical profiles of VpLAE and n-BF were assessed by liquid chromatography coupled to mass spectrometry, and their metabolites were putatively identified. Lastly, the possible biological activities related to the (anti) cytogenotoxicity of the compounds were predicted using the PASS online webserver. The in vivo results showed that different doses of VpLAE and n-BF did not present cytotoxic activity; however, the MN test revealed a slight mutagenic activity for the 24 h treatments. Moderate genotoxic effects were demonstrated for all treatments in the comet assay. Regarding anticytotoxicity and antimutagenicity, VpLAE and n-BF presented a high cytoprotective potential against DXR toxic effects. In the co-treatment, VpLAE reduced the DXR genotoxicity by ~27%, and n-BF did not demonstrate antigenotoxic potential. In contrast, an antigenotoxic effect was observed for both VpLAE and n-BF in the pre- and post-treatments, reducing DXR genotoxicity by ~41% and ~47%, respectively. Chemical analysis of VpLAE and n-BF showed the presence of eight phenolic compounds, including seven chlorogenic acids and a flavonoid. The PASS online tool predicted antimutagenic, anticancer, antineoplastic, chemoprotective, antioxidant, and radical scavenging activities for all constituents identified in VpLAE and n-BF. V. polyanthes leaves presented a protective effect against DXR cytogenotoxicity. In general, VpLAE and n-BF showed a greater antigenotoxic potential in the pre- and post-treatments. The metabolites putatively identified in VpLAE and n-BF exhibited antioxidant and chemoprotective potential according to computational prediction analysis. Altogether, our results highlight the potential application of V. polyanthes to protect against toxic manifestations induced by DXR.
The 2020 COVID-19 pandemic triggered a global search for effective treatments, leading to the exploration of drug repurposing strategies. This approach seeks to reuse existing medicines for emerging diseases. Studies have investigated the potential of drugs like Remdesivir in treating COVID-19. However, assessing the genotoxicity of medicines is crucial in pharmaceutical development to ensure they do not harm DNA. Common tests for this purpose are the Comet Assay and the Micronucleus Test. This study evaluated the genotoxic potential of Remdesivir in mice using the Comet Assay, which revealed genotoxic effects in all groups tested, mainly after 48 hours of exposure, the Micronucleus Test, which also showed genotoxicity in some groups and demonstrated cytotoxicity in all the cases. Molecular tests indicated an increase in the expression of the p53 gene, suggesting a response to genetic damage caused by Remdesivir and activation of DNA repair mechanisms. Furthermore, a decrease in bcl-2 gene expression implied a possible genotoxicity potential. These results raise concerns about the genetic safety of Remdesivir. Data suggests that Remdesivir may damage genetic material in mice. However, more research is needed to comprehensively understand the risks and benefits of Remdesivir, particularly in long-term patient settings.